本文已被:浏览 199次 下载 259次
Received:June 06, 2026 Published Online:September 24, 2026
Received:June 06, 2026 Published Online:September 24, 2026
中文摘要: 胃癌作为一种常见的恶性肿瘤,多数患者在确诊时已是局部晚期或发生远处转移,预后差。传统治疗方案如铂类及紫杉醇等化学治疗的效果不理想,且不良反应发生率较高,毒副反应大,患者难以耐受。抗体偶联药物是一类新兴的靶向治疗药物,近年来在胃癌治疗中引起了广泛关注。该类型药物具有精准、高效的特点,且已经显示出可靠的疗效和安全性,为胃癌患者提供了新的治疗选择,有望在未来取代传统治疗方案。本文对该类型药物在胃癌治疗中的研究进展进行综述。
Abstract:Gastric cancer,as a common malignant tumor,is often diagnosed at an advanced local stage or with distant metastasis,resulting in poor prognosis for most patients. Traditional treatment regimens,such as platinum-based therapies and paclitaxel,show unsatisfactory efficacy and a high incidence of adverse reactions,making them difficult for patients to tolerate. Antibody - drug conjugates(ADCs)are a new class of targeted therapeutic agents that have garnered extensive attention in the treatment of gastric cancer in recent years. ADCs are characterized by precision and high efficiency,and they have demonstrated reliable efficacy and safety,providing new treatment options for gastric cancer patients and potentially replacing traditional regimens in the future. This article aims to review the research progress of ADCs in the treatment of gastric cancer.
keywords: Gastric cancer Antibody - drug conjugate Targeted therapy Human epidermal growth factor receptor Trastuzumab deruxtecan Disitamab vedotin Trophoblast cell-surface antigen 2 Sacituzumab tirumotecan Enfortumab vedotin
文章编号: 中图分类号:R735.2 文献标志码:A
基金项目:
| Author Name | Affiliation |
| XU Yixuan,WANG Tianyi,WU Jianqiu | Department of Medical Oncology,Nanjing Medical University Affiliated Cancer Hospital,Nanjing,Jiangsu 210009,China |
| Author Name | Affiliation |
| XU Yixuan,WANG Tianyi,WU Jianqiu | Department of Medical Oncology,Nanjing Medical University Affiliated Cancer Hospital,Nanjing,Jiangsu 210009,China |
引用文本:
